Home Metabolism PPAR

PPAR Antagonists

Cat.No. Product Name Information Product Use Citations Product Validations
S2871 T0070907 T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.
Nucleic Acids Res, 2025, 53(14)gkaf669
Cell Rep Med, 2025, 6(10):102373
Apoptosis, 2025, 30(5-6):1391-1409
Verified customer review of T0070907
S2915 GW9662 GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM in a cell-free assay, with at least 10- to 600-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ.
J Extracell Vesicles, 2025, 14(8):e70143
Stem Cell Res Ther, 2025, 16(1):347
Genes Dis, 2025, 12(3):101333
Verified customer review of GW9662
S2798 GW6471 GW 6471 is a potent antagonist of PPARα with IC50 of 0.24 μM.
Mol Cancer, 2025, 24(1):34
Cell Mol Immunol, 2025, 10.1038/s41423-025-01338-y
Apoptosis, 2025, 30(5-6):1391-1409
S8025 GSK3787 GSK3787 is a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
JACC Basic Transl Sci, 2025, 10(7):101222
Drug Des Devel Ther, 2024, 18:4799-4824
Cell Discov, 2023, 9(1):54
Verified customer review of GSK3787
S5817 GSK0660 GSK0660 is a potent PPARβ/δ antagonist with a pIC50 of 6.8 (binding assay IC50 = 155 nM; antagonist assay IC50 = 300 nM) and is nearly inactive on PPARα and PPARγ with IC50s above approximately 10 μM.
Cells, 2024, 13(3):206.
Cells, 2024, 13(3)206
Elife, 2023, 12e82970
S0531 DG172 dihydrochloride DG-172 dihydrochloride is a novel PPARβ/δ-selective antagonist with the IC50 of 27 nM.
Cell Signal, 2022, 93:110304
E8300New Amezalpat Amezalpat acts as a PPARα antagonist with an IC50 value of 58 nM. This compound demonstrates antineoplastic effects.
S0773 Mifobate Mifobate (SR-202), a potent and specific PPARγ antagonist, selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM).